Generic sofosbuvir-based combinations may not perform as well as therapy based on branded sofosbuvir-containing regimens, according to result of a study conducted in Qatar and presented to the recent 2016 AASLD Liver Meeting. People treated with generics were less likely to have a sustained virological ...

Researchers have come up with the first direct evidence that enough hepatitis C virus (HCV) sheds into the rectums of HIV-positive men who have sex with men (MSM) to transmit directly to another man’s penis during anal sex, even when no blood is present. Publishing their ...

Mylan signs sub-license agreement with the Medicines Patent Pool to increase access to hepatitis C treatment in developing countries HERTFORDSHIRE, England and BENGALURU, India, Nov. 28, 2016 — Mylan N.V. (NASDAQ, TASE: MYL) today announced that the company has signed an agreement with the Medicines Patent ...

Research carried out by Mount Sinai Medical Center, New York, found that non-adherence was the strongest risk factor for treatment failure in people taking sofosbuvir/ledipasvir (Harvoni). The main reasons cited for non-adherence were failing to take medication as prescribed and hospitalisation. The findings were presented at ...

Who has hepatitis? Well, that’s a good question. We know that some groups are more likely to acquire HCV infection than others. But, unfortunately, most people who have the virus have not yet been diagnosed. November 2016 marks the fourth European Testing Week – and the ...

From 18 to 25 November 2016, almost 500 organisations all across Europe are hosting activities to increase awareness of the benefits of HIV and hepatitis testing. These diseases can be asymptomatic for a long time and without getting tested, many people will live with their ...